FDA Memo Raises Questions About Possible COVID-19 Vaccine Links to Rare Child Deaths 
Novo Nordisk Appoints Greg Miley as Global Head of Corporate Affairs Amid U.S. Pricing Pressure 
Cogent Biosciences Soars 120% on Breakthrough Phase 3 Results for Bezuclastinib in GIST Treatment 
Canada Loses Measles-Free Status After Nearly 30 Years Amid Declining Vaccination Rates 
Trump Hints at Major Autism Announcement, Raises Questions on Tylenol Link 
Eli Lilly’s Inluriyo Gains FDA Approval for Advanced Breast Cancer Treatment 
Pfizer Boosts Bid for Metsera Amid Intensifying Rivalry with Novo Nordisk in Obesity Drug Market 
Bayer’s Stroke Drug Achieves Breakthrough Trial Results, Boosting Market Confidence 
Trump and Merck KGaA Partner to Slash IVF Drug Costs and Expand Fertility Coverage 
Novo Nordisk and Eli Lilly Lower Prices for Weight-Loss Drugs Amid U.S. Agreement 
Major Drugmakers Slash U.S. Prices and Sell Directly to Patients Amid Trump’s Push for Affordable Medicines 
Eli Lilly’s Weight-Loss Pill Nears Fast-Track FDA Approval as Profits Surge on Global Demand 
Innovent’s Xinermei Intensifies Weight-Loss Drug Battle in China 
Novartis to Acquire Avidity Biosciences for $12 Billion to Strengthen Rare Muscle Disorder Portfolio 
Merck Nears Acquisition of Cidara Therapeutics at Significant Premium 
It’s a new age for science as the US Food and Drug Administration gave its approval for scientists to conduct genetic manipulation in an effort to combat leukemia. This could potentially lead to a cure that does not require extensive chemotherapy, but it is also a new frontier. Gene-editing technology has existed for decades but it wasn’t until recently that it became much cheaper and more accessible.
For all intents and purposes, genetic manipulation can be used for practically any end for as long as it has something to do with organic materials. In the case of humans, the tool called CRISPR can allow scientists to finally start cutting away or adding specific genetic materials that can change a person’s physiology. With regards to leukemia, scientists want to alter cells to make them more resistant to the disease, the New York Times reports.
By creating tougher and more aggressive cells to fight leukemia or other forms of cancer, patients would theoretically never have to take medicine of any kind ever again. They would have a living drug in their system, which would make them practically immune to fatal diseases.
Naturally, there are plenty of concerns when it comes to genetic manipulation that makes getting approval for tests incredibly difficult. The company that finally got approval is Novartis and one of the company’s biggest achievements is 12-year-old Emily Whitehead who is now free of leukemia thanks to the revolutionary treatment.
When speaking to the FDA panel before approval was granted, Emily’s father, Tom Whitehead made a passionate case in favor of the treatment. The premise was simple; approve the treatment and thousands will be saved, Futurism reports.
“I hope that someday all of you on the advisory committee can tell your families for generations that you were part of the process that ended the use of toxic treatments like chemotherapy and radiation as standard treatment, and turned blood cancers into a treatable disease that even after relapse most people survive.”
